explore -WSS

explore

author：fashion 2025-09-03 03:43:07 - browse：543

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Bispecific antibodies are next new thing in cancer immunotherapy

WSS

Ebola: Gilead Sciences antiviral shows promise as new treatment

Bispecific antibodies are next new thing in cancer immunotherapy

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

The thinking behind the controversial eating disorder chatbot Tessa

Living organ donors deserve priority status for transplants

leisure time

explore

Wikipedia

At least 13 dead in Texas as scorching temps continue

Senate panel passes drug pricing bills, but drops one PBM reform

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

John Green on his newest strategy for fighting tuberculosis

What does generative AI mean for health care? We asked experts

Boston's new lab space is opening empty

Walensky prepares to leave CDC — and Congress — behind

WuXi out of biotech trade group, U.S. and China relations to blame

In age of alternative facts, a scholarly course on calling out crap

First U.S. drug developed to treat liver disease MASH is approved

focus

Can medical device makers keep up in the race to treat obesity?

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

How many hemophilia patients actually want gene therapy?

Bispecific antibodies are next new thing in cancer immunotherapy

HHS secretary Becerra pressed on Change HealthCare cyberattack

Millions may soon lose Medicaid when they don't have to

leisure time

leisure time

Wikipedia

focus